Colectomy for Colorectal Cancer: 115 Real Stories

115 stories match colorectal cancer and colectomy. 112 of them mention surgery.

Cancer Stories

A patient, who was diagnosed with Stage IV Colorectal AdenocarcinomaColorectal Cancer

Pembrolizumab led to complete response before surgery for metastatic dMMR colon cancer

Patient Info: Anonymized, male, 70+ | Stage IV

Biomarkers: dMMR/MSI-H; MLH1 loss; PMS2 loss; BRAF mutation; heterozygous MUTYH p. pathogenic variant

Metastatic Site: liver

The 2023 liver resection showed a pathological complete response with no residual tumor, and he entered follow-up without additional therapy.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Colorectal AdenocarcinomaColorectal Cancer

Colorectal cancer: using a blood test (ctDNA) to guide immunotherapy after surgery — Case 1

Patient Info: Anonymized, Male, 50s

Biomarkers: KRAS ; TMB 11 mutations/Mb; loss of MLH1 and PMS2; dMMR/MSI-H; germline multigene panel negative; ctDNA positive after surgery and chemotherapy

Pembrolizumab cleared ctDNA within about 3 months. After completing 1 year of immunotherapy, surveillance CT showed no evidence of disease and ctDNA remained negative.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Colorectal AdenocarcinomaColorectal Cancer

Colorectal cancer: using a blood test (ctDNA) to guide immunotherapy after surgery

Patient Info: Anonymized, Male, 40s

Biomarkers: dMMR/MSI-H; pathogenic germline MLH1 c.1459C>T consistent with Lynch syndrome; postoperative ctDNA rose during chemotherapy and became near-undetectable on pembrolizumab

He continued pembrolizumab with no evidence of disease on interval CT and near-undetectable ctDNA. Grade 1 thyroiditis was monitored without treatment interruption.

PubMed Central
OutcomeIn Treatment
Ceejay, who was diagnosed with Stage III Colorectal CancerColorectal Cancer

Stage III Colorectal Cancer: Ceejay's Patient Story

Patient Info: Ceejay | Stage III

After treatment, Ceejay describes feeling optimistic and hopeful while planning for retirement and new hobbies.

Our Cancer Stories
OutcomeNot reported
Patricia, who was diagnosed with Colorectal CancerColorectal Cancer

Colorectal Cancer: Patricia's Patient Story

Patient Info: Patricia

Receiving a 6-month course of oral capecitabine while continuing ostomy care and recovery from postoperative complications.

Our Cancer Stories
OutcomeCare Ongoing
Laura, who was diagnosed with Stage III Colorectal AdenocarcinomaColorectal Cancer

Stage III Colorectal Adenocarcinoma: Laura's Patient Story

Patient Info: Laura | Stage III

Laura completed about 6 months of chemotherapy after partial colectomy and returned to part-time work while continuing to manage fatigue.

Our Cancer Stories
OutcomeNot reported
A patient, who was diagnosed with Stage II Colorectal CancerColorectal Cancer

J Fletcher

Patient Info: J Fletcher | Stage II

J Fletcher was awaiting the start of planned surgery and chemotherapy after a recent Stage II colorectal cancer diagnosis.

Our Cancer Stories
OutcomeCare Ongoing
Lori, who was diagnosed with Stage IV Colorectal CancerColorectal Cancer

Stage IV Colorectal Cancer: Lori's Survivor Story

Patient Info: Lori | Stage IV

Metastatic Site: ovary

After a September 2024 recurrence and surgery in October, Lori said she was in remission and was being monitored with monthly blood work.

Our Cancer Stories
OutcomeCancer-Free / NED
Dan, who was diagnosed with Colorectal CancerColorectal Cancer

Colorectal Cancer: Dan's Survivor Story

Patient Info: Dan Gut, Male, Under 40

As of March 2022, Dan had recovered quickly after minimally invasive total colectomy for extensive precancerous colon polyps and intramucosal carcinoma, did not need chemotherapy, and reported better energy while adapting diet and bowel habits.

Cleveland Clinic
OutcomeSurvivorship / Surveillance
A patient, who was diagnosed with Colorectal CancerColorectal Cancer

Colon cancer at age 27 in a man later diagnosed with Lynch syndrome

Patient Info: Anonymized, Male, Under 40

Biomarkers: Germline pathogenic MSH2 variant NM_000251.2:c.942+3A>T identified later

The first colon cancer remained disease-free after partial colectomy and adjuvant chemotherapy; years later, he died after decline from metastatic pheochromocytoma.

PubMed Central
OutcomeIn Memory
A patient, who was diagnosed with Colorectal AdenocarcinomaColorectal Cancer

A second colon cancer leading to a Lynch syndrome diagnosis

Patient Info: Anonymized, Male, 40s

Biomarkers: Complete loss of MSH2 and MSH6 nuclear staining in the cecal tumor; germline pathogenic MSH2 variant NM_000251.2:c.942+3A>T; Lynch syndrome.

The cecal cancer was treated with complete colectomy, while later presumed recurrences were ultimately identified as meningiomas and metastatic pheochromocytoma; he died after the pheochromocytoma progressed.

PubMed Central
OutcomeIn Memory
Li, who was diagnosed with Colorectal CancerColorectal Cancer

Colorectal Cancer: Li's Patient Story

Patient Info: Li Zong

Li Zong remained on chemotherapy and targeted therapy while considering future hospice and palliative care.

Our Cancer Stories
OutcomeCare Ongoing